AsymBio Inaugurates New CDMO Facility in Shanghai’s Fengxian District

• AsymBio, a subsidiary of Asymchem Laboratories, has inaugurated its new CDMO facility in Fengxian, Shanghai, to support late-stage clinical and commercial manufacturing of biologics.

• The facility spans 120,000 m², with Phase IA now operational and Phase IB set for completion by late 2025, expanding capabilities for antibody-drug conjugates (ADCs).

AsymBio, the CDMO subsidiary of Asymchem Laboratories, has officially launched its new manufacturing base in Fengxian, Shanghai. The 120,000-square-metre facility will provide late-stage clinical and commercial manufacturing services for antibodies and bioconjugates.

The first phase of the site, now operational, includes antibody drug substance (DS) production with 2,000L single-use bioreactors and purification lines. It also features antibody drug product (DP) capabilities, including B+A grade fill-finish lines with an open restricted access barrier system (ORABS) and a 20 m² lyophilizer supporting 2R-20R vial formats. Phase IB, expected to be completed by late 2025, will introduce ADC DS and DP manufacturing capabilities. Future expansions will include quality control laboratories, R&D centres, and operational hubs.

The Fengxian Facility complements AsymBio’s existing GMP-compliant Jinshan site, which already provides antibody and ADC production services at various scales, ranging from 200L to 2,000L for antibody DS and 100L to 500L for ADC DS. The company’s manufacturing operations adhere to regulatory guidelines from the NMPA, FDA, EMA, and ICH, with a track record of successful EU QP audits and multinational client inspections.

Currently, AsymBio supports 21 out of 27 Chinese biopharma companies engaged in ADC licensing-out projects, reinforcing its role as a key partner in the bioconjugate supply chain.